100% autologous tissue regeneration

Our technology enables the production of a complete autologous engineered tissue composed of extracellular matrix and cells derived from patients’ own tissues. The matrix is a thermo-responsive hydrogel, prepared by decellularization of patient’s omentum sample, while the cells are re-programmed from patient’s mature cells to form induced Pluripotent Stem Cells (iPSCs). Ex-vivo differentiation of iPSCs within the thermo-responsive hydrogel leads to the generation of a functional mature tissue.

Learn More
Patient's blood is collected to produce induced Pluripotent Stem Cells (iPSCs)
Small sample of patient's omentum
undergoes a proprietary
decellularization process to form a thermo-responsive hydrogel
The stem cells are differentiated within the hydrogel to generate the desired tissue
The autologous engineered tissue is implanted to the patient

The future of Spinal Cord Injury (SCI) treatment

Our proprietary technology platform is the foundation for engineering autologous neural implants. Differentiation of iPSCs within extra cellular matrix (ECM) creates functional neural tissue implants that can bridge and regenerate injured spinal cord.


World’s first
3D-printed heart
using human cells

In 2019, Matricelf licensed from Tel Aviv University the technology that enabled printing the first 3D human heart from human cells

Novel tissue
engineering technology
addressing multiple
clinical indications

Matricelf’s novel regenerative medicine platform aims to treat a range of medical conditions including Spinal Cord Injuries (SCI), Age-related Macular Degeneration (AMD), Parkinson’s Disease, Myocardial Infarction, etc.

Awards and Recognition

Contact Us

Feel free to drop us a line!